Section Arrow
Quote
ALNY.NASDAQ
- Alnylam Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/03 02:06 EST
Regular Hours
Last
 456.04
+6.48 (+1.44%)
Day High 
459.77 
Prev. Close
449.56 
1-M High
495.55 
Volume 
1.82M 
Bid
455.7
Ask
456.2
Day Low
441.22 
Open
449 
1-M Low
436.5119 
Market Cap 
58.93B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 472.49 
20-SMA 467.33 
50-SMA 460.6 
52-W High 495.55 
52-W Low 205.87 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.47/11.19
Enterprise Value
60.18B
Balance Sheet
Book Value Per Share
1.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.25B
Operating Revenue Per Share
13.15
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
INTSIntensity Therapeutics0.7302-0.5898-44.68%-- 
ADTXAditxt Inc0.0594-0.0086-12.65%-- 
RANIRani Therapeutics Holdings2.2+0.75+51.72%-- 
MNOVMedicinova1.66+0.47+39.50%-- 
RXRXRecursion Pharmaceuticals5.52-0.13-2.30%-- 
Quotes are at least 15-min delayed：2025/11/03 02:06 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.